Cargando…
Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms
BACKGROUND: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymeno...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128821/ https://www.ncbi.nlm.nih.gov/pubmed/12201901 |
_version_ | 1782120338872598528 |
---|---|
author | Mingomataj, Ervin Priftanji, Alfred Qirko, Etleva Dinh, Q Thai Fischer, Axel Peiser, Christian Groneberg, David A |
author_facet | Mingomataj, Ervin Priftanji, Alfred Qirko, Etleva Dinh, Q Thai Fischer, Axel Peiser, Christian Groneberg, David A |
author_sort | Mingomataj, Ervin |
collection | PubMed |
description | BACKGROUND: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymenoptera venom in the mediterranean population of Albania. METHODS: A retrospective study was performed using the clinical reports of 37 patients with venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT. The protocol lasted 3 – 4 d with an increase in the concentration from 0.01 μg/ml to 100 μg/ml. Anaphylactic reactions were classified according to the Mueller-classification. RESULTS: The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an end dose of 100 μg. CONCLUSIONS: Rush-SIT is a reliable method for the treatment of anaphylactic reactions to hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause higher numbers allergic reactions than wasp or paperwasp Rush-SIT. |
format | Text |
id | pubmed-128821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-1288212002-10-23 Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms Mingomataj, Ervin Priftanji, Alfred Qirko, Etleva Dinh, Q Thai Fischer, Axel Peiser, Christian Groneberg, David A BMC Dermatol Research Article BACKGROUND: Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymenoptera venom in the mediterranean population of Albania. METHODS: A retrospective study was performed using the clinical reports of 37 patients with venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT. The protocol lasted 3 – 4 d with an increase in the concentration from 0.01 μg/ml to 100 μg/ml. Anaphylactic reactions were classified according to the Mueller-classification. RESULTS: The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an end dose of 100 μg. CONCLUSIONS: Rush-SIT is a reliable method for the treatment of anaphylactic reactions to hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause higher numbers allergic reactions than wasp or paperwasp Rush-SIT. BioMed Central 2002-08-30 /pmc/articles/PMC128821/ /pubmed/12201901 Text en Copyright © 2002 Mingomataj et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Mingomataj, Ervin Priftanji, Alfred Qirko, Etleva Dinh, Q Thai Fischer, Axel Peiser, Christian Groneberg, David A Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms |
title | Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms |
title_full | Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms |
title_fullStr | Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms |
title_full_unstemmed | Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms |
title_short | Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms |
title_sort | specific immunotherapy in albanian patients with anaphylaxis to hymenoptera venoms |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128821/ https://www.ncbi.nlm.nih.gov/pubmed/12201901 |
work_keys_str_mv | AT mingomatajervin specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms AT priftanjialfred specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms AT qirkoetleva specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms AT dinhqthai specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms AT fischeraxel specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms AT peiserchristian specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms AT gronebergdavida specificimmunotherapyinalbanianpatientswithanaphylaxistohymenopteravenoms |